Skip to main content
OpenTrials
Completed

NCT Number: NCT05386511

Real-world Study of UTD1 in Chinese Advanced Breast Cancer

To evaluate the efficacy and safety of UTD1 in patients with advanced breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged over 18 years old.
  • Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
  • Plan to receive or has received UTD1 monotherapy or UTD1 based therapy
  • Available medical history.

Exclusion criteria

1.Incomplete medical history.

Treatment and study plan

Primary outcomes

  1. PFS

    Time frame: 6 weeks

    Progression free survival

Secondary outcomes

  1. Adverse events

    Time frame: 6 weeks

    Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

An Observational, Real-world Study Study of UTD1 in Chinese Advanced Breast Cancer

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 23, 2022
Registry last updated
Feb 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.